We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Maelor | MLR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 100.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 100.00 | 100.00 |
| Top Posts |
|---|
Posted at 25/4/2008 15:34 by rgtaylor25 Don't break open the champagne just yet lollipop3!! MLR had a 1 for 7 share consolidation a week ago and you will see that the charts above have been converted in line with that consolidation of shares. |
Posted at 23/4/2008 18:53 by waxman3 Assegai - 23 Apr'08 - 17:45 - 1685 of 1686I respect none and nothing and am open about it. I neither give nor want respect. I not do I love shares so I cant fall out of love with them. I simply change strategy. Respect and a dollar will get you a good cup of cofffee in most States of the UNION. MLR has never treated its private sharholders fairlym I was glad topmove out and on, I maay or may not look back in a few years but will keep a note of them. To me they are just a small corner shop, next to a shopping Mall right now ocassionally peddling a few whares away from the store, with a music box and monkey on a stick. Time will tell At 90p they are still only 12.85p old value. I sold at 14.25p |
Posted at 14/4/2008 07:59 by pheasant1 I am astounded at the lack of information provided by MLR on its latest acquisition. However, the directors did find time to talk to Edison Research, who kindly provide a research note here:Just put in the company search box. Registration is required (though free), and the note can then be downloaded as a PDF. The usual copyright conditions apply. Once you have the note, the company's general reticence to discuss the deal becomes a little clearer; gross revenues for SEPI were just a tad under £2m - almost all from Haemopressin, plus some coppers from Cortirel. The note seems well written, and it finds reasonable upside from Haemopressin sales as new regulatory approvals come through (in terms of both extended indications and additional territories). In the short term, Edison forecasts an EBITDA for year ending March 2008 of £1.63m. As the year end date has just passed, it seems safe to assume that this is spot on. The mid and long-term projections seem to be fairly conservative, with a number of possible revenue sources being excluded for prudence' sake - on this basis, EBITDA for FY 2010 is £4.9m. My conclusion is that the long-term impact of this acquisition is potentially positive (as you might hope when the company is forking out £14.25m), but the short term gain is negligible. The bad news is that MLR has paid more than 7 times REVENUE for SEPI (and almost 16 times EBITDA), which is pretty outlandish for nothing more than a royalty stream (SEPI has no personnel, no sales people, no marketing, no nothing). I reckon that two or three times sales AT MOST would have been in keeping with recent deals, with a further premium always possible for a decent patent position (distinctly lacking here), or for specific know-how (ditto). Better management, better market share and position, better patents and so on all add up to higher value when buying a company. MLR gets none of these. This deal seems to underscore the deal-making prowess of Apax rather than astute management at MLR. And as usual, the PI pays. |
Posted at 12/4/2008 15:12 by gogoneko All I see is an absence of argument for the "huge premium" claim based on any fact, i.e. nobody has disputed that the 10x pro forma EBITDA payment is too much - which is what MLR have used for their valuation. Simply putting forward a bunch of assumptive "what if" cases relating to the competitor suddenly deciding to squeeze MLR out of certain markets should be reflected in a risk factor in the share price, not the amount MLR should have paid.More "what if"s: What if Ferring decides that the market is too small to defend or has bigger fish to fry? What if regulatory approval for Haemopressin isn't given? Why does the £2m milestone payment only relate to "certain products" approval in UK, France and Italy only? Was that year's EBITDA an anomaly?, etc, etc. We're only going to know over time whether the amount paid was too much or not but I think the company is turning its back on PIs so with that attitude I'm never going to hold long-term. As quite a few others are questioning director motives the shares could drop as investors lose confidence/interest even though the company currently has a profitable and growing business even though it'll still be settling payments 4-5 years hence. The danger has always been though that the company would overpay on expansion and at the first sign of things not going to plan then the shares will be hit - so far, from a performance perspective, the company have delivered. |
Posted at 12/4/2008 11:47 by waxman3 No one louder than me, but it ain't going to happen as I CANT SING.Read this again please and try to digest what is being said then your over the pound a share figure my be plausible in about 10 years. For Gawd's sake get wise and analys this latest scam and the products MLR has paid a huge premium for SEPI, SEPI competes with Ferring who have an almost identical product to Terlipressin under differnt branding and much larger market share. Ferring could swamp MLR or IS PHARMA plc, as it proposes name change to. |
Posted at 11/4/2008 20:17 by waxman3 gogoneko - 31 Mar'08 - 14:38 - 1660 of 1669I'm not surprised that the share price isn't sinking that much as the company is increasingly looking in better shape with the addition of more profitable revenue streams and expanded markets. For Gawd's sake get wise and analys this latest scam and the products MLR has paid a huge premium for SEPI, SEPI competes with Ferring who have an almost identical product to Terlipressin under differnt branding and much larger market share. Ferring could swamp MLR or IS PHARMA plc, as it proposes name change to. So we have now 7 shares of 10p in Maelor consolidated into 1 new share of 70p I am wagering now, revising my estimate down, that it will settle around 50p Also take a look at this Talk about keeping it in th circle. Look as if the priavte shareholder has been shafted again. But then I did tell you all to sell some time back when I got wind of these things. And of course took your sh(t again over exposing dog shares. Tim may have been great as an employee of ELAN, but the hot seat is different and too date he has clearly demdisableded that its not an easy ride at the top.! |
Posted at 31/3/2008 07:45 by rcktmn I sold this morning...had anough.. slight profit.. gone into HMB instead !Good luck to all remaining holders. Knowing my luck MLR will probably double in the next 12 months! |
Posted at 28/3/2008 16:10 by steeplejack The placing discount at over 20% to yesterday's closing price is larger than you might have hoped but i'm sure the broker has done a bit of quiet enquiry to find out what an acceptable placing price for interested institutions would be. I reckon if you rang up Noble and told 'em you were a holder they'd cut you into the placing.MLR had a rights some years back at 25p from memory and it was near fully taken up.Thing is,rights issues are time-consuming and expensive,underwriti As far as the new management is concerned ,i'd guess they're keen to build a new institutional client base given the company's past track record and share price performance.Anyway,o |
Posted at 18/2/2008 14:32 by waxman3 The agguement is really quite simply.MLR still has a substantial private shareholder base, some still very loyal the the share price they bought in at, many up to two pounds a share. There was always a risk of institutional dumping when the new MLR was floated at 10p. I believe that substance could have been given to the floatation had the private investors been allowed a slice of the action. Private shareholder being as they are, really quite a loyal old bunch. You are now experiencing the proof of the pudding as the share price dirts no matter what the director do now. |
Posted at 04/8/2007 16:54 by piruxi GOGONEKO well done a a fairly good attempt marred only by a lack of thorough research/MLR has clearly stated its priorities are focussed on the UK market. I would not worry to much about its NHS profits as MLR supplies the NHS at very competitive prices If anyone wants an extra source of information- You can check out MLR sales of Optiflo, at least, which are prescribed on the NHS on here and search for "prescription cost analysis" you will find there is steady growth of optiflo usage in the NHS, but you may have to search further for MLR's other products which I believe are ordered directly by hospital inventory teams. Whereas I was not, what you could say, a 1000% happy with the recent placing price, I was later assurred that this was the best and most cost effective way to go forward. Of course there are negative comments, there always are, and of course I was dissappointed with the SP, as I am still. However I believe that there is still the old manangement image overhang and the fact that MLR is still seen as the old company instead of the new one the Accorus deal created. However I have 1000% yes 1000% confidence in the Tim and the team. Obviously gogoneko is not into the art of the psychologial path of investor research, as if he/she were then clearly it would be realised how silly his first time lucky statement is. Tim was able to take a year off no less after ELAN to enjoy his passion which is sailing, before making a chosey re-entery into business. Given his ethical business connections and those of the other board members, together with the appointment of NG as FD, then clearly this company is not one that is perpared to underperform/ Last year when I looked at this MLR was on track to be in profit in the next year or two, well it has achieved that now and more and will I believe still concentrate more on the UK while keeping an eagle eye on all potentials(see report referred to below), however the days of a monopolistic tag are way way off into the future as Tim Wright would be mindful of the follies of that label. Furthermore, it could be reasoned that Sales and Marketing Directors cost money. MLR already has a top class team of profession sales executives who are reporting directly back to Tim and as this next set of figures will show are driving sale ahead, therfore "if it aint broke why fix it" Finally I see no exceptionals in the coming years as clearly the deferring of the Accorus payements was a good indicator there would be none. I would suggest for an more indepth look at the company you see the EDISON Report, is can be found here, and starts of with the following----Apr 05------2007 Transforming acquisition Maelor has agreed in principle to acquire Acorus Therapeutics, a privately held UK company, for a maximum of £13m in cash and shares, a substantial portion of which is deferred and subject to an earn-out. The move represents a significant step in the ongoing transformation of Maelor under its new management team. It is designed strategically to create a self-sustaining and fast growing group capable of pursuing the classic acquisition-led, low R&D "speciality pharma" model. Research type: Review - Acquisition Its a good seven page report, and gee Choooochieeeeeee Cooes, it goes way beyond my attention span as I usually pick 'em without too much time on research which make it work rather than fun. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
